Zonisamide for the Treatment of Obstructive Sleep Apnea in Overweight/Obese Patients
This study is ongoing, but not recruiting participants.
Sponsor:
Göteborg University
Collaborator:
Eisai Inc.
Information provided by (Responsible Party):
Jan Hedner, Göteborg University
ClinicalTrials.gov Identifier:
NCT01765608
First received: January 8, 2013
Last updated: January 10, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This RCT explores the efficacy of Zonisamide (Zonegran®)on overweight/obese in patients with moderate to severe obstructive sleep apnea. Patients will be randomized to receive zonisamide, placebo or nasal continuous positive airway pressure (nCPAP) during 4 weeks. A 5 month open extension part will follow when patients in the tablet groups will all receive zonisamide. Patients in the open CPAP group will continue with CPAP treatment.
Study hypothesis:
Controlled pharmacological weight reduction with Zonisamide will result in elimination of OSA and OSA sequels more effectively than nCPAP due to incomplete compliance with the mechanical treatment and a lack of direct beneficial metabolic effects after nCPAP. Further it is hypothesized that zonisamide has a direct pharmacological effect on respiratory control during sleep by its carbonic anhydrase inhibitory effects and this will result in a reduction of sleep disordered breathing.
| Condition | Intervention | Phase |
|---|---|---|
|
Sleep Apnea Obstructive Sleep Apnea Obesity |
Drug: Zonisamide Drug: Placebo Device: nCPAP |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A 1 Month Randomized Placebo Controlled, Double Blind Trial With a 5 Month Open Extension Phase to Explore the Efficacy of Zonisamide on Apnea/Hypopnea Index in Overweight/Obese Sleep Apnea Patients. |
Resource links provided by NLM:
Further study details as provided by Göteborg University:
Primary Outcome Measures:
- Primary objective is to investigate the effect of zonisamide vs. placebo on sleep disordered breathing after short-term (4 weeks) treatment. [ Time Frame: Baseline to 4 weeks. ] [ Designated as safety issue: Yes ]The primary objective of this study is to explore the efficacy of pharmacological weight reduction on obstructive sleep apnea (OSA) by assessment of apnoea/hypopnea index (AHI) and oxygen desaturation index (ODI) 4 weeks .
Secondary Outcome Measures:
- Longterm efficacy and effect of zonisamide on obstructive sleep apnea (OSA)in comparison to CPAP by assessment of apnoea/hypopnea index (AHI) after 24 weeks. [ Time Frame: baseline to 24 weeks ] [ Designated as safety issue: Yes ]The effect of CPAP will be expressed in terms of apnea alleviation. Other secondary objectives include the effect on oxygen desaturation, mean overnight oxygenation, sleep quality (by polysomnographic assessment), daytime sleepiness, daytime cognitive function, patient-reported outcomes, blood pressure and effects on metabolic markers.
- Secondary objective is to investigate the effect of zonisamide vs. placebo on other sleep disordered breathing parameters after short-term (4 weeks) treatment. [ Time Frame: Baseline to 4 weeks. ] [ Designated as safety issue: Yes ]Secondary objectives include the effect on other markers of sleep apnea like mean overnight oxygenation, sleep quality (by polysomnographic assessment), daytime sleepiness, daytime cognitive function, patient-reported outcomes, blood pressure and effects on metabolic markers after short term treatment (4 weeks).
| Enrollment: | 50 |
| Study Start Date: | March 2010 |
| Estimated Study Completion Date: | June 2013 |
| Estimated Primary Completion Date: | June 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Zonisamide
Zonisamide (Zonegran®) 300 mg. Hard white capsule. The total length of zonisamide treatment will be 20 and 24 weeks ± 2 weeks including one or two 4 week titration phases in the placebo and zonisamide groups respectively. Dosing will be down titrated after finished study during 2-3 weeks.The maximum dose after titration will be administrated once daily. Evening medication should be taken 2 hours before bedtime. The tablets will be swallowed with 200 ml of water (room temperature) in an upright body position.
|
Drug: Zonisamide
Zonisamide (Zonegran®) tablets will be administered according to a forced stepwise weekly titration scheme with weekly 100 mg escalations from 100 to 300 mg daily according to the manufacturer Eisai Inc.
Other Name: Zonegran®
|
|
Active Comparator: Placebo
Matched for Zonisamide. Hard white capsule. Manufactured by Eisai Inc. Placebo tablets will be administered according to a forced stepwise weekly titration scheme with weekly 1 tablet escalations from 1 to 3 tablets daily matching the Zonisamide (Zonegran ®) dosing regimen for a total duration of 4 weeks. Evening medication should be taken 2 hours before bedtime. The tablets will be swallowed with 200 ml of water (room temperature) in an upright body position.
|
Drug: Placebo |
|
Active Comparator: nCPAP
Continuous positive nasal airway pressure (nCPAP) delivers slightly pressurized air throughout the breathing cycle and will be given through a mask that is placed and secured over the person's nose. nCPAP titration will follow clinical routines whereby the patient is equipped with an autotitrating device (Sullivan S8 or S9). The standard setting is a pressure delivery in the pressure range 5-15 mbar and the full treatment is maintained in the patient´s home. The adequate performance of the device is controlled by user time readers and built-in memory cards and control readings are routinely performed within the first 4 weeks of treatment initiation. Patients will be encouraged via telephone calls for maximum use. Total duration of CPAP treatment is 24 weeks.
|
Device: nCPAP
Other Names:
|
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Provision of informed consent prior to any study specific procedures
- Males/females 18 to 75 years
- An Apnea-Hypopnea Index (AHI)>15
- Epworth Sleepiness Scale score (ESS)>6
- Body mass index (BMI) between >27 and <35 kg/m2 (mild to moderate)
- Clinically normal physical findings and laboratory values, as judged by the investigator
Exclusion Criteria:
- Hypersensitivity to sulfonamides or zonisamide.
- History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity
- Subjects with a seizure disorder
- Clinically significant renal (serum creatinine >2.0 mg/dL or >130 µmol/L), neurological, metabolic (e.g. Type 1 or 2 diabetes), haematological or hepatic disease (ASAT or ALAT >2 times the upper limit of normal).
- Subjects who have taken any weight loss medications (prescription or over-the-counter) within one month prior to Enrollment
- Subjects with occupations designated as high risk or safety sensitive including patients who have to handle complex machinery or are professional drivers where there may be an increased risk for work or traffic accidents.
- Unstable angina pectoris
- Unstable hypertension (diastolic blood pressure above 100 on treatment for more than 3 months), diabetes (fasting plasma glucose above 7 mmoles/l)
- Uncontrolled congestive heart failure
- Myocardial infarction or coronary vessel intervention within the previous 6 months period
- Subjects with uncontrolled hypertension (defined as a diastolic blood pressure ≥100 mmHg and/or a systolic blood pressure ≥180 mmHg with or without medication). Hypertensive subjects on medications must have been on the same dose of the same antihypertensive medication for at least two months prior to Enrollment.
- Previously diagnosed or treated clinically significant cardiac arrhythmia
- Clinically significant chronic pulmonary or gastrointestinal disease
- Clinical history of depression as judged by the investigator or other previous or present clinically significant psychiatric disease
- Pregnancy or lactation. Women of childbearing potential should use effective birth control prior to and during the study
- Suspected or confirmed poor compliance
- Alcohol or drug abuse during the last year
- Subjects with any other significant condition that, in the opinion of the investigator, could interfere with participation in the study.
- Severe nocturnal hypoxia defined as more than 10 episodes with an oxygen desaturation exceeding 50% or signs of lacking resaturation between desaturations on previous recordings according to investigators judgement.
- Participation in another clinical study during the last 6 months
- Inability to understand and complete the questionnaires
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01765608
Locations
| Sweden | |
| Center for Sleep and Vigilance Disorders | |
| Gothenburg, Västra Götaland, Sweden, 40530 | |
Sponsors and Collaborators
Göteborg University
Eisai Inc.
Investigators
| Principal Investigator: | Jan Hedner, MD. Prof. | Department of Internal Medicine. Center for Sleep and Vigilance Disorders |
More Information
No publications provided
| Responsible Party: | Jan Hedner, MD, Professor, Göteborg University |
| ClinicalTrials.gov Identifier: | NCT01765608 History of Changes |
| Other Study ID Numbers: | ZON-01, 2009-015859-24 |
| Study First Received: | January 8, 2013 |
| Last Updated: | January 10, 2013 |
| Health Authority: | Sweden: Regional Ethical Review Board |
Keywords provided by Göteborg University:
|
Obstructive Sleep apnea Zonisamide Zonegran Apnea Respiration Disorders Sleep Disorders Obesity |
Anti-Obesity Agents Carbonic Anhydrase Carbonic Anhydrase Inhibitors Enzyme Inhibitors Sulfonamides Therapeutic Uses Pharmacologic Actions |
Additional relevant MeSH terms:
|
Sleep Apnea Syndromes Sleep Apnea, Obstructive Apnea Obesity Overweight Respiration Disorders Respiratory Tract Diseases Signs and Symptoms, Respiratory Signs and Symptoms Overnutrition Nutrition Disorders Body Weight Sleep Disorders, Intrinsic Dyssomnias |
Sleep Disorders Nervous System Diseases Carbonic Anhydrase Inhibitors Zonisamide Anti-Obesity Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Antioxidants Protective Agents Physiological Effects of Drugs Anticonvulsants Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 16, 2013